Bergholm R, Tiikkainen M, Vehkavaara S, et al. 2003. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium- dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care, 26:1667–72. Betteridge DJ, Verges B. 2005. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia, 48:2477–81. Bruemmer D, Blaschke F, Law RE. 2005. New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes (Lond), 29(Suppl 1)S26–30. Caballero AE. 2005. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res, 36:241–9. Caldwell SH, Argo CK, Al-Osaimi AM. 2006. Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol, 40:S61–6. Charbonnel B, Schernthaner G, Brunetti P, et al. 2005. Long-term efﬁcacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia, 48:1093–4. Chen K, Li F, Li J, et al. 2006. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med, 12:425–32. Chiquette E, Ramirez G, Defronzo R. 2004. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med, 164:2097–104. Dailey GE 3rd, Noor MA, Park JS, et al. 2004. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med, 116:223–9. DeFronzo RA. 2004. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am, 88:787–835, ix. DeFronzo RA, Goldberg M, Agus ZS. 1976. The effects of glucose and insulin on renal electrolyte transport. J Clin Invest, 58:83–90. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. 1985. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest, 76:149–55. Delerive P, Martin-Nizard F, Chinetti G, et al. 1999. Peroxisome proliferator- activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activa- tor protein-1 signaling pathway. Circ Res, 85:394–402. Derosa G, Cicero AF, Gaddi A, et al. 2005a. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on pro- thrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract, 69:5–13. Derosa G, Cicero AF, Gaddi AV, et al. 2005b. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12- month, double-blind, randomized clinical trial. Clin Ther, 27:1383–91. Di Cicco RA, Allen A, Carr A, et al. 2000. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol, 40:1280–5. Dormandy JA, Charbonnel B, Eckland DJ, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROac- tive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366:1279–89. Einhorn D, Rendell M, Rosenzweig J, et al. 2000. Pioglitazone hydrochlo- ride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther, 22:1395–409. Fonseca V, Rosenstock J, Patwardhan R, et al. 2000. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA, 283:1695–702. Fryer LG, Parbu-Patel A, Carling D. 2002. The Anti-diabetic drugs rosigli- tazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem, 277:25226–32. Gastaldelli A, Miyazaki Y, Pettiti M, et al. 2002. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab, 87:5098–103. Vascular Health and Risk Management 2007:3(4) Thiazolidinediones in combination with metformin Gerstein HC, Yusuf S, Bosch J, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368:1096–105. Ginsberg H, Kimmerling G, Olefsky JM, et al. 1975. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest, 55:454–61. GlaxoSmithKline. 2007. Avandamet: summary of product characteristics [online]. URL: http://us.gsk.com/products/assets/us_avandamet.pdf Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. 2002. Efﬁcacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev, 18:127–34. Granner DK, O’Brien RM. 1992. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care, 15:369–95. Haffner SM, Lehto S, Ronnemaa T, et al. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339:229–34. Haffner SM, Stern MP, Hazuda HP, et al. 1990. Cardiovascular risk fac- tors in conﬁrmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA, 263:2893–8. Hardie DG, Carling D, Carlson M. 1998. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem, 67:821–55. Hawley SA, Davison M, Woods A, et al. 1996. Characterization of the AMP-activated protein kinase kinase from rat liver and identiﬁcation of threonine 172 as the major site at which it phosphorylates AMP- activated protein kinase. J Biol Chem, 271:27879–87. Howard BV, Rodriguez BL, Bennett PH, et al. 2002. Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiol- ogy. Circulation, 105, e132–7. Hundal RS, Krssak M, Dufour S, et al. 2000. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 49:2063–9. Inzucchi SE, Maggs DG, Spollett GR, et al. 1998. Efﬁcacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 338:867–72. Kato K, Satoh H, Endo Y, et al. 1999. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial func- tion. Biochem Biophys Res Commun, 258:431–5. Kendall DM, Rubin CJ, Mohideen P, et al. 2006. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone- comparative study. Diabetes Care, 29:1016–23. Kersten S, Desvergne B, Wahli W. 2000. Roles of PPARs in health and disease. Nature, 405:421–4. Kirpichnikov D, McFarlane SI, Sowers JR. 2002. Metformin: an update. Ann Intern Med, 137:25–33. Knowler WC, Barrett-Connor E, Fowler SE, et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393–403. Large V, Beylot M. 1999. Modiﬁcations of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Diabetes, 48:1251–7. Lee Y, Hirose H, Ohneda M, et al. 1994. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA, 91:10878–82. Lillioja S, Mott DM, Howard BV, et al. 1988. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med, 318:1217–25. Magnusson I, Rothman DL, Katz LD, et al. 1992. Increased rate of gluconeo- genesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest, 90:1323–7. 509